Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

 
The Bastide Group enters the respiratory care devices market in Italy
The Bastide Group enters the respiratory care devices market in Italy

Caissargues, July 18, 2022

The Bastide Group announces the acquisition of a majority stake in Oxystore, a company based near Milan, Italy. Oxystore specializes in home diagnosis and online sales of

 
BASTIDE : Acceleration in growth in the third quarter, to 6% - Outlook confirmed
BASTIDE : Acceleration in growth in the third quarter, to 6% - Outlook confirmed

Caissargues, May 12, 2022

 

In €k 2020-2021 2021-2022 Change 3rd quarter revenue 111,669 118,446 +6.1% 9-month revenue 333,033 341,491 +2.5%

 

 

Group

The Non-Financial Rating Agency Vigeo-Eiris Classifies Korian 1st Company in the Healthcare Sector for its ESG1 Commitments
The Non-Financial Rating Agency Vigeo-Eiris Classifies Korian 1st Company in the Healthcare Sector for its ESG1 Commitments


Korian (Paris:KORI), the leading European care services company for elderly and fragile people, welcomes the report published early October by the non-financial rating agency Vigeo-Eiris (V.E), a

Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the European Respiratory Society (ERS) International Congress 2021
Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the European Respiratory Society (ERS) International Congress 2021


Regulatory News:



Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE)

EOS imaging Reports its Full Year 2020 Results and First Quarter 2021 Revenues
EOS imaging Reports its Full Year 2020 Results and First Quarter 2021 Revenues


Regulatory News:



EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

EOS Imaging Reports Full-Year 2020 Revenue up +19% Year-on-year
EOS Imaging Reports Full-Year 2020 Revenue up +19% Year-on-year


Regulatory News:



EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

EOS imaging Announces Its Financial Agenda For 2021
EOS imaging Announces Its Financial Agenda For 2021


Regulatory News:



EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”
Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”


Regulatory News:



Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) a biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and Mauna

Mauna Kea Technologies Announces Two New Publications Demonstrating the Efficacy, Safety and Accuracy of Cellvizio® for Pancreatic Cyst Evaluation
Mauna Kea Technologies Announces Two New Publications Demonstrating the Efficacy, Safety and Accuracy of Cellvizio® for Pancreatic Cyst Evaluation


Regulatory News:



Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (pCLE/nCLE)

EOS imaging Reports 9-month Revenue up +32% Year-on-year
EOS imaging Reports 9-month Revenue up +32% Year-on-year


Regulatory News:



EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

EOS imaging: First EOSedge™ Installation in Australia
EOS imaging: First EOSedge™ Installation in Australia


EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, announces the

EOS imaging: First EOSedgeTM Installation in Australia
EOS imaging: First EOSedgeTM Installation in Australia


Regulatory News:



EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

EOS imaging Reports Its 2020 Half-year Financial Results
EOS imaging Reports Its 2020 Half-year Financial Results


Regulatory News:



EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

First EOSedgeTM installation in the United States
First EOSedgeTM installation in the United States


EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announces

EOS Imaging Reports Strong Revenue Growth for Half Year 2020
EOS Imaging Reports Strong Revenue Growth for Half Year 2020


Regulatory News:



EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

EOS imaging Announces the First EOSedge™ Installation in Germany
EOS imaging Announces the First EOSedge™ Installation in Germany


Regulatory News:



EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), the leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical

EOS imaging: Availability of the 2019 Annual Financial Report in English
EOS imaging: Availability of the 2019 Annual Financial Report in English


EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning

Mauna Kea Technologies: Cellvizio® Endorsed By the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) as a Safe and Effective Diagnostic Tool
Mauna Kea Technologies: Cellvizio® Endorsed By the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) as a Safe and Effective Diagnostic Tool


Regulatory News:



Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE)

EOS imaging Reports Its Full Year 2019 Results and First Quarter 2020 Revenues
EOS imaging Reports Its Full Year 2019 Results and First Quarter 2020 Revenues


Regulatory News:



EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

Alphatec Holdings Terminates Tender Offer Agreement with EOS imaging
Alphatec Holdings Terminates Tender Offer Agreement with EOS imaging


Regulatory News:



EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME) ("EOS"), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical

EOS imaging Announces the Rescheduling of the Publication of Its Annual Results
EOS imaging Announces the Rescheduling of the Publication of Its Annual Results


Regulatory News:



EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

Mauna Kea Technologies Receives FDA Clearance And CE Marking For Its Next-Generation Cellvizio® Platform
Mauna Kea Technologies Receives FDA Clearance And CE Marking For Its Next-Generation Cellvizio® Platform


Regulatory News:



Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE)

EOS imaging: Information Relating to the Total Number of Share Capital and Voting Rights
EOS imaging: Information Relating to the Total Number of Share Capital and Voting Rights


Regulatory News:



EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination
Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination


Regulatory News:



Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (pCLE/nCLE)

EOS imaging Announces First Installation of EOSedge™ in North America
EOS imaging Announces First Installation of EOSedge™ in North America


Regulatory News:



EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and